<DOC>
	<DOCNO>NCT01875367</DOCNO>
	<brief_summary>GEICAM/2012-07 study phase III , prospective , open , randomize , multicenter national design assess patient preference intravenous ( IV ) subcutaneous ( SC ) trastuzumab , within SC administration vial device self-administration patient disseminate breast cancer HER2 . Approximately 195 patient include receive subcutaneous trastuzumab fix dose 600 mg every 3 week 4 cycle ( 2 administer injection vial syringe 2 injection device ) . Following administration four cycle , patient decide whether continue subcutaneous formulation trastuzumab every 3 week progression . Since randomization study start subcutaneous trastuzumab , patient receive treatment cycle intravenous trastuzumab usual . Main objective : Proportion patient indicate preference use subcutaneous v intravenous trastuzumab . This principal primary objective analyze answer questionnaire experience preference patient ( Principal endpoint ) The duration study estimate 34 month .</brief_summary>
	<brief_title>A Phase III Clinical Trial Evaluate PatientÂ´s Preference Subcutaneous Trastuzumab ( SC ) Versus Intravenous ( IV ) Administration Patients With HER2 Positive Advanced Breast Cancer ( ABC ) .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Woman , 18 year old upper . Patient advance breast cancer HER2 positive histologically confirm . The criterion positivity HER2 : IHC 3 + IHQ2 + FISH / CISH / SISH positive HER2 amplification ( * ) FISH / CISH / SISH positive HER2 amplification ( * ) ( * ) Defined ratio copy HER2/neu copy centromere chromosome 17 ( CEP17 ) &gt; 2.2 , number copy HER2/neu &gt; 6 , per local laboratory criterion . Patient receive trastuzumab without chemotherapy hormonal therapy least 4 month . No evidence disease progression ( clinical / radiological ) least 4 month inclusion study life expectancy least 3 month . Adequate performance status : Eastern Cooperative Oncology Group ( ECOG ) &lt; 2 . Adequate bone marrow function , liver kidney Proper cardiac function ( LVEF within normal limit center , measure echocardiography MUGA ) . The patient must inform study must sign date inform consent document entry trial . The patient must willing able comply study procedure available answer study questionnaire . Patients advance breast cancer . Breast cancer patient tumor HER2negative . The patient another active malignancy breast adenocarcinoma ; exclude nonmelanoma skin cancer properly treat situ neoplasia . Patients history malignancy , bear &gt; 5 year without evidence disease could include . The patient uncontrolled brain metastasis . Concomitant administration , 4 week prior study entry , experimental treatment . Known hypersensitivity trastuzumab component . Patients severe dyspnea rest require supplemental oxygen . Heart disease serious medical pathological prevent trastuzumab administration : documented history CHF , highrisk arrhythmia uncontrolled angina require medication , clinically significant valvular disease , history myocardial infarction evidence transmural infarction ECG hypertension poorly control . Presence concomitant serious systemic disease incompatible study ( discretion investigator ) . The patient pregnant lactating . Women childbearing potential undergo pregnancy test blood urine within 14 day prior inclusion institutional rule use nonhormonal contraceptive suitable : intrauterine device , barrier method ( condom diaphragm ) also use conjunction spermicidal cream , total abstinence surgical sterilization , treatment study drug 6 month follow end treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Subcutaneous trastuzumab</keyword>
	<keyword>Intravenous trastuzumab</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>